论文部分内容阅读
目的预测T2DM患者由预混人胰岛素(BHI30)转为双时相门冬胰岛素30(BIAsp30)后治疗达标的基线特征。方法纳入A1chieve研究中BHI30血糖控制效果不佳而转用BIAsp30治疗的中国患者,以治疗24周后HbA_1c是否达标(<7.0%)为因变量,患者基线特征为自变量,行单因素及多因素回归分析。结果基线HbA_1c、FPG及体重是患者接受BIAsp30治疗后HbA_1c达标的预测因素。基线HbA_1c水平每增加1%,治疗后HbA_1c达标的可能性降低25%;基线FPG水平每增加1mmol/L,治疗后HbA_1c达标的可能性降低7%;基线体重每增加1kg,治疗后HbA_1c达标的可能降低2%。结论本研究提示,由BHI30转为BIAsp30治疗,患者基线HbA_1c、FPG及体重越低,血糖控制的达标率越高。
Objective To predict the baseline outcome of treatment in patients with T2DM after switching from BHI30 to BIAsp30. Methods The A1chieve study included Chinese patients treated with BIAsp30 with poor blood glucose control in BHI30, and whether HbA_1c reached the standard (<7.0%) after 24 weeks of treatment as the dependent variable. The baseline characteristics of the patients were independent variables, single and multiple factor regression analysis. Results Baseline HbA 1c, FPG and body weight were the predictors of HbA 1c compliance in patients receiving BIAsp30 treatment. For each 1% increase in baseline HbA_1c levels, the likelihood of achieving HbA_1c reduction after treatment was reduced by 25%; for every 1 mmol / L increase in baseline FPG levels, HbA_1c was reduced by 7% after baseline treatment; for every 1 kg increase in baseline body weight, HbA_1c May be reduced by 2%. Conclusions This study suggests that the lower the baseline HbA_1c, FPG and body weight from BHI30 to BIAsp30, the higher the compliance rate of glycemic control.